Explore more publications!
The Georgian Health Digest
Got News to Share?

The Georgian Health Digest: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Georgian Health Digest.

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

Press releases published on December 18, 2025

Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference
December 18, 2025

Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference

Indeterminate GlobeNewswire
Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion
December 18, 2025

Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion

Indeterminate GlobeNewswire
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease
December 18, 2025

ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease

Indeterminate GlobeNewswire
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease
December 18, 2025

ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease

Indeterminate GlobeNewswire
Kane Biotech Announces Closing of Private Placement Offering with an Insider of the Company
December 18, 2025

Kane Biotech Announces Closing of Private Placement Offering with an Insider of the Company

Indeterminate GlobeNewswire
CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock
December 18, 2025

CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock

Indeterminate GlobeNewswire
NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion
December 18, 2025

NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion

Indeterminate GlobeNewswire
Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million
December 18, 2025

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million

Indeterminate GlobeNewswire
Memo Therapeutics AG’s Potravitug Granted Orphan Designation in the European Union
December 18, 2025

Memo Therapeutics AG’s Potravitug Granted Orphan Designation in the European Union

Indeterminate GlobeNewswire
Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
December 18, 2025

Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Indeterminate GlobeNewswire
CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries
December 18, 2025

CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries

Indeterminate GlobeNewswire
Kamada Announces a $10-$14 Million Extension of Canadian Supply Tender
December 18, 2025

Kamada Announces a $10-$14 Million Extension of Canadian Supply Tender

Indeterminate GlobeNewswire
Nutriband Differentiates Prescription Fentanyl from Illicit Fentanyl in Response to United States Executive Order Designating Fentanyl as a Weapon of Mass Destruction
December 18, 2025

Nutriband Differentiates Prescription Fentanyl from Illicit Fentanyl in Response to United States Executive Order Designating Fentanyl as a Weapon of Mass Destruction

Indeterminate GlobeNewswire
Atavistik Bio Raises $120 Million Series B Financing to Advance the Development of Selective Allosteric Small Molecule Therapeutics for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT) and Myeloproliferative Neoplasms (MPNs)
December 18, 2025

Atavistik Bio Raises $120 Million Series B Financing to Advance the Development of Selective Allosteric Small Molecule Therapeutics for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT) and Myeloproliferative Neoplasms (MPNs)

Indeterminate GlobeNewswire
BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes
December 18, 2025

BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes

Indeterminate GlobeNewswire
Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 18, 2025

Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Indeterminate GlobeNewswire
Lifecore Biomedical to be Added to Nasdaq Biotech Index
December 18, 2025

Lifecore Biomedical to be Added to Nasdaq Biotech Index

Indeterminate GlobeNewswire
Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease
December 18, 2025

Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease

Indeterminate GlobeNewswire
Avadel Pharmaceuticals Announces Completion of Enrollment in Phase 3 REVITALYZ™ Trial in Idiopathic Hypersomnia
December 18, 2025

Avadel Pharmaceuticals Announces Completion of Enrollment in Phase 3 REVITALYZ™ Trial in Idiopathic Hypersomnia

Indeterminate GlobeNewswire
Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination
December 18, 2025

Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions